Treatment of Resectable Malignant Brain Tumors

2014-08-27 03:40:59 | BioPortfolio


The goals of this study are to evaluate each of the following items:

1. Time to recurrence in patients receiving brachytherapy with the GliaSite RTS

2. Overall survival (OS) in patients with malignant brain tumors who are undergoing surgical resection and brachytherapy treatment with the GliaSite® Radiation Therapy System (RTS).

3. Incidence of serious adverse events in patients treated with GliaSite RTS


Your doctor has found that you have a brain tumor that needs to be surgically removed. Your doctor has explained the risks and benefits of the surgery. After the brain tumor is surgically removed, some tumor may be left. A treatment that sends additional radiation right to the place around where the tumor was located, may help kill any tumor cells left after the surgery. This treatment is called brachytherapy. Your doctor has explained the risks and benefits of brachytherapy. Researchers in this study would like to evaluate a radiation delivery system, GliaSite RTS, that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.

The GliaSite RTS is a balloon attached to the end of a tube with an access port. The balloon will be put in the space left behind after your tumor is taken out. The end of the tube with its access port will be on the outside of your skull, underneath the skin, at the top of your head. The balloon is filled with radiation therapy solution to provide radiation therapy to any remaining tumor cells next to the space where the tumor was removed.

Before your already scheduled surgery, a series of tests will be performed to find out if you qualify for participation in this study. You will have a complete medical history and your temperature, blood pressure, and pulse will be measured. A standard neurological exam will be performed, in which your mental status, vision, sensory functions, speech, motor skills, and functioning will be evaluated. Women who are able to have children must have a negative urine or blood pregnancy test. A MRI/CT scan will be taken of your head. As part of this MRI/CT, you will get an injection of a contrast solution into your vein. The MRI/CT images will show if there is brain swelling or bleeding. It will also show the edges of the tumor area and will be used to confirm that you should receive radiation therapy with the GliaSite RTS.

If you qualify for the study, you will have a small balloon (GliaSite) placed in the space where the tumor was removed during your surgery. The balloon will be filled with an x-ray dye and normal saline (sterile water with salt) to make sure that the balloon properly fills the space where the tumor was removed. Your surgeon will then stitch your head closed. It is possible that your surgeon may decide not to place the GliaSite device in the space where the tumor was. If your surgeon chooses not to place the GliaSite device, you will be offered alternative treatments, once you recover from surgery.

The balloon will be filled with an x-ray dye solution once it has been placed in the surgical cavity and will be kept filled until it is replaced by the radioactive solution. You will then have an MRI/CT of the head. Following this MRI/CT exam, you will get an injection of a contrast solution into your vein. You will then have a second MRI/CT exam of the head, which will show this contrast solution. The MRI/CT images will show if there is brain swelling or bleeding. It will also show the edges of the tumor area and where the balloon is located. These images will be used to confirm that you should receive radiation therapy with the GliaSite RTS device. You may also have x-ray films of the brain to confirm balloon placement. You may be able to leave the hospital after surgery.

You may be readmitted to the hospital for radiation therapy about one to two weeks after surgery. Twenty-four hours before starting radiation therapy, you will begin taking a medication and continue taking it for 24 hours after your radiation therapy is finished. This medication, an iodine-potassium iodide solution, keeps your thyroid gland from gathering too much radiation in the event that the balloon leaks.

Before the radiation therapy is begun, x-ray films of the brain may be taken to show the location of the balloon and verify the balloon is still properly placed. Once the placement of the balloon is confirmed, the x-ray dye and saline are removed from the catheter. The balloon will then be filled with radiation therapy solution and normal saline.

You may be able to go home once the material has been put into the balloon. If this is done, special instructions will be given to you that you must follow if you are sent home. You must then return to the hospital at the appropriate time for removal of the radioactive material. Otherwise, you will be in the hospital the entire time you are getting radiation therapy.

When the radiation therapy is completed after about 3 to 7 days, the radiation therapy solution will be removed from the balloon. The GliaSite device will be rinsed with normal saline. This rinsing helps lessen any radioactivity remaining in the device. After completion of brachytherapy, the balloon will be completely emptied and the GliaSite device will be surgically removed. When your doctor feels that you are ready, you will be discharged from the hospital.

Following the completion of brachytherapy, you may receive other forms of radiation therapy as prescribed by your physician. This is usually done as an outpatient.

You will be asked to follow up with your doctor at certain time points after you receive the brachytherapy treatment. The time points are 1 month and 3 months after brachytherapy and then every 3 months after that (for example, 1, 3, 6, 9, 12, 15, 18, 21 and 24 months).

During these follow up visits, you will be asked to complete a mini-mental status examination referred to as a MMSE. You will be asked to complete a quality of life questionnaire. Your physician may take an MRI or CT image of your brain if he/she thinks it is necessary.If you have undergone a second operation for your brain cancer, you will be asked about this surgery. You will be asked about any steroid medication you are taking and if the dose has changed since your last visit. Your doctor will also ask you about any other cancer medications or treatments you have received since your last visit.You and your doctor may discuss any serious events that have happened to you since your last visit.

This is an investigational study. The device is FDA approved. About 300 patients will take part in this multicenter study. Up to 20 will be enrolled at M. D. Anderson.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Brain Tumor


GliaSite Radiation Therapy System


U.T.M.D. Anderson Cancer Center
United States




M.D. Anderson Cancer Center

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:40:59-0400

Clinical Trials [4569 Associated Clinical Trials listed on BioPortfolio]

GliaSite 1-3 Mets Study

This study has been designed to compile information on the efficacy of the GliaSite RTS combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells. It is...

Lithium and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Primary Cancer Outside the Brain

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as lithium, may protect normal cells from the side effects of radiation therapy. Giving lithium togeth...

Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs, such as riluzole, may make tumor cells more sensitive to radiation therapy. Giving riluzole together with w...

Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tha...

PubMed Articles [29593 Associated PubMed Articles listed on BioPortfolio]

Oxygen-guided radiation therapy.

It has been known for over a hundred years that tumor hypoxia, a near-universal characteristic of solid tumors, decreases the curative effectiveness of radiation therapy. However, to date, there are n...

Radiation and Brain Tumors: An Overview.

The use of radiation is an essential part of both modern cancer diagnostic assessment and treatment. Next-generation imaging devices create 3D visualizations, allowing for better diagnoses and improve...

Radiation-induced vascular malformations in the brain, mimicking tumor in MRI-based treatment response assessment maps (TRAMs).

•Of 310 brain tumors patients recruited, histology of 99 lesions was available.•Of those, 5 were histologically confirmed as radiation-induced malformations.•TRAMs cannot differentiate active tu...

Radiation-Induced Gliomas.

Radiation therapy has been a cornerstone of cancer management for many decades and is an integral part of the multi-modality care of patients with brain tumors. The known serious side effects of radia...

50 Gy Stereotactic Body Radiation Therapy to the Dominant Intra-Prostatic Nodule: Results from a Phase Ia/b Trial.

Although localized prostate cancer (PCa) is multifocal, the dominant intraprostatic nodule (DIN) is responsible for disease progression after radiation therapy. PCa expresses antigens that could be re...

Medical and Biotech [MESH] Definitions

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).

A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.

Organs which might be damaged during exposure to a toxin or to some form of therapy. It most frequently refers to healthy organs located in the radiation field during radiation therapy.

Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. military, purposes.

More From BioPortfolio on "Treatment of Resectable Malignant Brain Tumors"

Quick Search


Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...

Searches Linking to this Trial